ArticlePediatric rheumatology online journal2026
An analysis of clinical manifestations and therapeutic outcomes in pediatric connective tissue disease-associated interstitial lung disease.
Article in Pediatric rheumatology online journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Initial Dosage Optimization of Tacrolimus in Connective Tissue Disease-Associated Interstitial Lung Disease Patients: An Exploratory Study.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPediatric connective tissue disease-associated interstitial lung disease (CTD-ILD) is a rare but serious condition with limited clinical data; this study aimed to evaluate its clinical features, treatment strategies, and outcomes.
methodsA single-center retrospective study included 50 pediatric CTD-ILD patients with complete follow-up data from June 2018 to February 2024. Collected variables included age at CTD-ILD diagnosis (years), sex, underlying CTD, respiratory symptoms, chest HRCT findings, pulmonary function parameters (VC, FVC, FEV₁, FEV₁/FVC%, TLC, DLco), treatment regimens, and outcomes. All patients underwent HRCT, and follow-up data were obtained from electronic medical records.
resultsThe median onset age was 10 years, with a female-to-male ratio of 4.56:1. Systemic lupus erythematosus (27/50, 54.00%) was the most common underlying disease, followed by MCTD and pSS. Nearly one-third of the patients (18/50, 36.0%) were asymptomatic; the most common symptom was cough (17/50, 34.0%), followed by dyspnea (8/50, 16.0%) and hypoxemia (6/50, 12.0%), while hemoptysis was rare (1/50, 2.0%). On HRCT, ground-glass opacities were the most common finding (25/50, 50.0%), followed by reticulation (11/50, 22.0%). All patients received corticosteroids for induction; CTX was used in 24/50 (48.0%) and MMF in 23/50 (46.0%). During maintenance, MMF was used in 45/50 (90.0%) of cases. Pulmonary function improved significantly at six and 12 months (P < 0.05), and HRCT showed radiological improvement in all patients with no progression at 1 year.
conclusionPediatric CTD-ILD often has an insidious onset with non-specific respiratory symptoms. Chest HRCT and pulmonary function testing are important tools for early evaluation and detection. In our cohort, treatment with corticosteroids and immunosuppressants was associated with improvements in lung function and imaging findings, supporting the potential benefit of early recognition and timely management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.